# Mining anticoagulant peptides from Poecilobdella manillensis by peptidomics analysis

**Authors:** Han-xue Zheng, Xiao-li Deng, Teng-teng Li, Guo-hua Xia, Huan Yang, Jiang-song Peng, Yu-ping Shen

PMC · DOI: 10.1007/s13659-025-00573-0 · Natural Products and Bioprospecting · 2026-02-02

## TL;DR

This study identifies anticoagulant peptides from a medicinal leech, focusing on a highly active peptide named LE-11 that shows promise for treating thrombotic diseases.

## Contribution

The study introduces LE-11, a novel anticoagulant peptide from Poecilobdella manillensis, validated for in vitro and in vivo anticoagulant activity.

## Key findings

- LE-11 significantly prolonged APTT and TT in vitro (P < 0.0001).
- LE-11 outperformed heparin in alleviating carrageenan-induced thrombosis in mice at 20 mg/kg.
- 1533 low-molecular-weight peptides were identified from P. manillensis, with 40.76% under 3000 Da.

## Abstract

Thrombosis triggers various severe diseases, while antithrombotic drugs carry bleeding risks, making the development of novel natural anticoagulants a subject of widespread attention. Poecilobdella manillensis, a prevalent medicinal leech, exhibits remarkable anticoagulant and antithrombotic activities. However, the material basis underlying its anticoagulant effects remains insufficiently investigated. This study aims to mine anticoagulant peptides from P. manillensis by peptidomics analysis, elucidate the material basis of its anticoagulant activity, and provide candidate molecules for developing novel natural anticoagulant drugs. Proteins extracted from P. manillensis were enzymatically digested and fractionated using DEAE-52 and CN columns. The resulting peptide components were analyzed by UPLC-Q-Orbitrap HRMS, and peptide sequences were matched against proteomic databases using Proteome Discoverer. Anticoagulant peptides were predicted using the BIOPEP-UWM database and PeptideRanker server, followed by in vitro and in vivo activity validation. Results showed that the hydrolysate consisted predominantly of low-molecular-weight peptides. 1533 peptides with Mw < 3000 Da (length < 20 amino acids) were identified from the PM-A2 and PM-A3 fractions, accounting for 40.76% of the total. Four peptides selected through predictive screening demonstrated anticoagulant and antithrombotic activities in vitro. Among them, LE-11 significantly prolonged both APTT and TT (P < 0.0001). Furthermore, LE-11 effectively alleviated carrageenan-induced thrombosis in mice, outperforming the heparin control at the mid-concentration (20 mg/kg). In this study, the highly active anticoagulant peptide LE-11 was identified from P. manillensis through peptidomic analysis. These findings establish a solid foundation for developing anticoagulant drugs from this source and provide critical scientific support for its clinical application in treating thrombotic diseases.

The online version contains supplementary material available at 10.1007/s13659-025-00573-0.

## Linked entities

- **Diseases:** thrombosis (MONDO:0000831)

## Full-text entities

- **Genes:** F2 (coagulation factor II) [NCBI Gene 14061] {aka Cf-2, Cf2, FII}, Gcg (glucagon) [NCBI Gene 14526] {aka GLP-1, Glu, PPG}, Ace (angiotensin I converting enzyme) [NCBI Gene 11421] {aka CD143}, Dpp4 (dipeptidylpeptidase 4) [NCBI Gene 13482] {aka Cd26, Dpp-4, THAM}, pma (peroneal muscular atrophy) [NCBI Gene 18849], Plg (plasminogen) [NCBI Gene 18815] {aka Pg}
- **Diseases:** heart attacks (MESH:D009203), platelet (MESH:D001791), peripheral vascular diseases (MESH:D016491), inflammatory (MESH:D007249), vein (MESH:D000071078), hemolysis (MESH:D006461), type 2 diabetes (MESH:D003924), cancers (MESH:D009369), C (OMIM:211750), venous thromboembolic disorders (MESH:D054556), bleeding (MESH:D006470), toxicity (MESH:D064420), stroke (MESH:D020521), thromboembolic diseases (MESH:D013923), Thrombosis (MESH:D013927), hypertension (MESH:D006973)
- **Chemicals:** hematoxylin (MESH:D006416), PBS (MESH:D007854), paraffin (MESH:D010232), NaCl (MESH:D012965), DEAE Cellulose (MESH:D003636), water (MESH:D014867), captopril (MESH:D002216), CN (MESH:C011206), CaCl2 (MESH:D002122), paraformaldehyde (MESH:C003043), carrageenan (MESH:D002351), Coomassie Blue (MESH:C048139), H&amp;E (MESH:D006371), exenatide (MESH:D000077270), eosin (MESH:D004801), Na (MESH:D012964), acetonitrile (MESH:C032159), LTKFEGVSDEE (-), LR- (MESH:D007852), sodium citrate (MESH:D000077559), sulfate (MESH:D013431), heparin (MESH:D006493), NaOH (MESH:D012972), SDS (MESH:D012967), trifluoroacetic acid (MESH:D014269), formic acid (MESH:C030544), hydrochloric acid (MESH:D006851)
- **Species:** Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Mus musculus (house mouse, species) [taxon 10090], Bothrops jararaca (jararaca, species) [taxon 8724], Hirudinaria manillensis (species) [taxon 1348078]
- **Cell lines:** SE-16 — Homo sapiens (Human), Xeroderma pigmentosum, Finite cell line (CVCL_ZM74), -11 — Homo sapiens (Human), Transformed cell line (CVCL_C1JD)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12862037/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12862037/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12862037/full.md

---
Source: https://tomesphere.com/paper/PMC12862037